Lixte Biotechnology (NASDAQ:LIXT) Trading 4.2% Higher – Still a Buy?

Shares of Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) traded up 4.2% on Tuesday . The company traded as high as $7.99 and last traded at $7.51. 614,310 shares traded hands during mid-day trading, an increase of 21% from the average session volume of 506,337 shares. The stock had previously closed at $7.21.

Analysts Set New Price Targets

Several research analysts have commented on LIXT shares. Weiss Ratings cut shares of Lixte Biotechnology from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, May 26th. Wall Street Zen raised Lixte Biotechnology to a “hold” rating in a report on Saturday, June 13th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Lixte Biotechnology has a consensus rating of “Sell”.

Lixte Biotechnology Price Performance

The stock has a market capitalization of $112.80 million, a P/E ratio of -6.65 and a beta of 1.24. The stock’s fifty day moving average is $6.18 and its two-hundred day moving average is $4.29.

Lixte Biotechnology (NASDAQ:LIXT) last issued its quarterly earnings results on Thursday, May 14th. The company reported ($0.18) earnings per share for the quarter.

Institutional Trading of Lixte Biotechnology

A number of institutional investors have recently bought and sold shares of LIXT. Renaissance Technologies LLC lifted its stake in Lixte Biotechnology by 47.0% in the fourth quarter. Renaissance Technologies LLC now owns 107,500 shares of the company’s stock valued at $422,000 after acquiring an additional 34,350 shares during the last quarter. Federation des caisses Desjardins du Quebec increased its stake in shares of Lixte Biotechnology by 83.6% during the 4th quarter. Federation des caisses Desjardins du Quebec now owns 93,380 shares of the company’s stock worth $367,000 after purchasing an additional 42,530 shares during the last quarter. DRW Securities LLC raised its holdings in shares of Lixte Biotechnology by 11.6% during the 4th quarter. DRW Securities LLC now owns 54,126 shares of the company’s stock valued at $213,000 after purchasing an additional 5,645 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of Lixte Biotechnology by 25.9% in the 4th quarter. Geode Capital Management LLC now owns 52,163 shares of the company’s stock valued at $205,000 after purchasing an additional 10,722 shares during the last quarter. Finally, XTX Topco Ltd acquired a new stake in shares of Lixte Biotechnology in the 4th quarter valued at $57,000. Institutional investors and hedge funds own 5.10% of the company’s stock.

Lixte Biotechnology Company Profile

Lixte Biotechnology Holdings, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for the treatment of cancer. The company’s research centers on selectively targeting key enzymes and pathways involved in DNA damage response and cell cycle regulation, with the goal of creating novel oncology drugs that improve patient outcomes with manageable safety profiles.

Lixte’s lead programs include selective inhibitors of cell cycle checkpoints and related targets, designed to potentiate the effects of standard-of-care chemotherapies and overcome resistance mechanisms.